[go: up one dir, main page]

BRPI0815415A2 - PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT - Google Patents

PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT

Info

Publication number
BRPI0815415A2
BRPI0815415A2 BRPI0815415-5A2A BRPI0815415A BRPI0815415A2 BR PI0815415 A2 BRPI0815415 A2 BR PI0815415A2 BR PI0815415 A BRPI0815415 A BR PI0815415A BR PI0815415 A2 BRPI0815415 A2 BR PI0815415A2
Authority
BR
Brazil
Prior art keywords
egfr inhibitor
inhibitor treatment
predictive marker
predictive
marker
Prior art date
Application number
BRPI0815415-5A2A
Other languages
Portuguese (pt)
Inventor
Paul Delmar
Barbara Klughammer
Verena Lutz
Patricia Mcloughlin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0815415A2 publication Critical patent/BRPI0815415A2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0815415-5A2A 2007-08-14 2008-08-07 PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT BRPI0815415A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07114292 2007-08-14
PCT/EP2008/006513 WO2009021674A1 (en) 2007-08-14 2008-08-07 Predictive markers for egfr inhibitor treatment

Publications (1)

Publication Number Publication Date
BRPI0815415A2 true BRPI0815415A2 (en) 2015-02-03

Family

ID=39884813

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815415-5A2A BRPI0815415A2 (en) 2007-08-14 2008-08-07 PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT

Country Status (9)

Country Link
EP (1) EP2188391A1 (en)
JP (1) JP2010535517A (en)
KR (1) KR20100037637A (en)
CN (1) CN101778954A (en)
AU (1) AU2008286407A1 (en)
BR (1) BRPI0815415A2 (en)
CA (1) CA2695485A1 (en)
MX (1) MX2010001571A (en)
WO (1) WO2009021674A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120095030A1 (en) * 2009-04-17 2012-04-19 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of tyrosine kinase inhibitors
CN108732350A (en) * 2017-04-20 2018-11-02 中国科学院上海生命科学研究院 PLA2G6 is as tubercle and the biomarker of early warning liver cancer in instruction liver
CN108732351A (en) * 2017-04-20 2018-11-02 中国科学院上海生命科学研究院 EPS8L2 is as tubercle and the biomarker of early warning liver cancer in instruction liver
CN108732349A (en) * 2017-04-20 2018-11-02 中国科学院上海生命科学研究院 LTA4H is as tubercle and the biomarker of early warning liver cancer in instruction liver
CN110780072B (en) * 2019-12-09 2021-08-06 四川大学华西医院 Application of APOO autoantibody detection reagent in preparation of lung cancer screening kit

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
WO2001079556A2 (en) * 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
AU2004211955B2 (en) * 2003-02-06 2009-05-14 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
KR101126560B1 (en) * 2003-05-30 2012-04-05 도꾜 다이가꾸 Process for predicting drug response
US8093011B2 (en) 2005-03-16 2012-01-10 Haley John D Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
AR053272A1 (en) * 2005-05-11 2007-04-25 Hoffmann La Roche DETERMINATION OF RESPONSIVES TO CHEMOTHERAPY
WO2007067500A2 (en) * 2005-12-05 2007-06-14 Genomic Health, Inc. Predictors of patient response to treatment with egfr inhibitors

Also Published As

Publication number Publication date
KR20100037637A (en) 2010-04-09
WO2009021674A1 (en) 2009-02-19
CA2695485A1 (en) 2009-02-19
CN101778954A (en) 2010-07-14
JP2010535517A (en) 2010-11-25
EP2188391A1 (en) 2010-05-26
MX2010001571A (en) 2010-03-15
AU2008286407A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
CY2017016I2 (en) PROTEASOMY INHIBITORS
BRPI0806898A2 (en) Mek inhibitors
EP2305306A4 (en) NEURO-INVASION INHIBITOR
BRPI0821129A2 (en) Methods for healing inhibition
BRPI0922880A2 (en) kinase inhibitor compounds
BRPI0813670A2 (en) TREATMENT COMPOUNDS
BRPI0812040A2 (en) INDICATIONS FOR ANTI-IL-I-BETA THERAPY
FR2911341B1 (en) CORROSION INHIBITOR
EP2177529A4 (en) NEW DE-SECRETASE INHIBITOR
BRPI0815415A2 (en) PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT
ATE522533T1 (en) PYRAZOLOPYRIMIDINONKINASE INHIBITOR
BRPI0814257A2 (en) predictive marker for egfr inhibitor treatment
BRPI0815545A2 (en) PREDICTIVE MARKERS FOR TREATMENT WITH EGFR INHIBITORS
BRPI0817361A2 (en) PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT
BRPI0814354A2 (en) PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT
BRPI0812105A2 (en) NERAMEXAN FOR NISTAGM TREATMENT
BRPI0715729A2 (en) glyt-1 inhibitors
BRPI0815414A2 (en) EGFR INHIBITOR TREATMENT MARKER
ES2395881T9 (en) Predictive marker for EGFR inhibitor treatment
BRPI0815546A2 (en) PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT
ES1064720Y (en) GUIDE FOR PERSIANA
FI20075320A0 (en) New useful inhibitors
BRPI0815372A2 (en) predictive marker for egfr inhibitor treatment
BRPI0821270A2 (en) Methods for healing inhibition
ES1067107Y (en) TRAIN FOR FOOTWEAR

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired